Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments

Wesnes, Keith, Gommoll, Carl, Chen, Changzheng, Sambunaris, Angelo, McIntyre, Roger and Harvey, Philip D. (2016) Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments. International Clinical Psychopharmacology, 32 (3). pp. 72-79. ISSN 0268-1315

[img]
Preview
Text
Effects_of_levomilnacipran_extended_release_on.99630 (1).pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives 4.0.

Download (285kB) | Preview
Official URL: http://dx.doi.org/10.1097/YIC.0000000000000157

Abstract

Performance-based cognitive data were collected using the Cognitive Drug Research System in a study of levomilnacipran extended-release (ER) 40-120 mg/day (NCT01034462) in adults with major depressive disorder. These data were analyzed post-hoc to explore the relationship between cognitive measures, depression symptoms (Montgomery-Asberg Depression Rating Scale, MADRS), and self-reported psychosocial functioning (Sheehan Disability Scale; SDS). Changes from baseline were analyzed in the intent-to-treat population and subgroups with impaired attention, as indicated by baseline Cognitive Drug Research System scores for Power of Attention and Continuity of Attention. Path analyses evaluated the direct and indirect effects of levomilnacipran ER on SDS total score change. Significantly greater improvements were observed for levomilnacipran ER versus placebo for Power of Attention, Continuity of Attention, MADRS, and SDS score changes; the mean differences were larger in the impaired subgroups than in the overall intent-to-treat population. Path analyses showed that the majority of SDS total score improvement (>=50%) was attributable to an indirect treatment effect through MADRS total score change; some direct effect of levomilnacipran ER on SDS total score improvement was also observed. In adults with major depressive disorder, levomilnacipran ER effectively improved measures of depression and cognition, which contributed toward reductions in self-reported functional impairment.

Item Type: Article
Uncontrolled Keywords: Antidepressant, cognition, depression, functioning, serotonin and norepinephrine reuptake inhibitor
Subjects: C800 Psychology
Department: Faculties > Health and Life Sciences > Psychology
Depositing User: Ellen Cole
Date Deposited: 06 Dec 2016 12:04
Last Modified: 01 Nov 2017 16:20
URI: http://nrl.northumbria.ac.uk/id/eprint/28781

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics


Policies: NRL Policies | NRL University Deposit Policy | NRL Deposit Licence